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A Ab bs st tr ra ac ct t
Polymorphisms in the ARLTS1 gene, a member of the Ras super-family, have been associated with susceptibility
in different cancer types. The involvement of the gene in apoptotic signalling motivated us to study the role of
ARLTS1 polymorphic variations in basal cell carcinoma of the skin (BCC). In a case-control study, 529 cases
diagnosed with BCC and 533 controls from Hungary, Romania and Slovakia were genotyped for the S99S
(297G>A), P131L (392C>T), L132L (396G>C), C148R (442T>C) and W149X (446G>A) polymorphisms
in the ARLTS1 gene. No significant association between any of the single nucleotide polymorphisms (SNP) and
risk of BCC (S99S, odds ratio (OR) 0.96, 95% confidence interval (CI) 0.60-1.53; P131L, OR 1.31 95%CI
0.74-2.31; L132L, OR 0.50, 95%CI 0.02-7.07; C148R, OR 0.50, 95%CI 0.69-1.18; and W149X, OR 1.01,
95%CI 0.37-2.79) was detected. Furthermore, no significant difference in the distribution of haplotypes due to
five polymorphisms in the ARLTS1 gene was found between the BCC cases and controls. Our data rule out an
association between variants in ARLTS1 and risk of BCC in the investigated population.
I In nt tr ro od du uc ct ti io on n
Basal cell carcinoma (BCC) is the most common skin
neoplasm, accounting for over 75% of all skin cancers
[1, 2]. Though BCC occurs mainly sporadically, multiple
tumours with an early onset are associated with rare
genetic disorders like Gorlin syndrome and xeroderma
pigmentosum [3]. BCC tumours grow slowly and seldom
metastasize; the recurrence and tissue destruction cause
extensive morbidity [4]. UV radiation is a major
environmental factor associated with increased incidence
of BCC due to increased leisure sun exposure [5, 6]. In
specific instances arsenic exposure has also been
associated with increased risk of non-melanoma skin
cancers, including BCC [7]. The aetiology of BCC
ultimately involves an interplay between genetic and
environmental factors like UV radiation.
BCC mainly originates through UV-mediated DNA
damage. The consequent mutations in the critical genes
result in growth advantage to the affected cells leading to
clonal expansion. Mechanistically apoptosis prevents
carcinogenesis by eliminating cells with excessive damage
that escape the DNA repair machinery [8]. We hypo-
thesized that variants in the genes involved in apoptosis
can potentially modulate disease susceptibility. Genetic
variants in critical genes can potentially modify susceptibility
to BCC through subtle influences on critical cellular
processes like DNA repair, cell cycle and apoptosis.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(1) 26
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ADP-ribosylation factor-like tumour suppressor 
gene 1 (ARLTS1) is a member of the Ras superfamily,
involved in apoptotic signalling. Previously this gene has
been suggested to be associated with susceptibility of
multiple cancer types [9]. Therefore in this study we
investigated the role of variants in the ARLTS1 gene on
BCC susceptibility in cases and matching controls
recruited from areas of Hungary, Romania and Slovakia.
M Ma at te er ri ia al ls s   a an nd d   m me et th ho od ds s
Study population: Cases and controls were recruited
as part of a large study on risk of various cancers due to
environmental exposures in Hungary, Romania and
Slovakia between 2002 and 2004. The recruitment was
carried out in the counties of Bacs, Bekes, Csongrad and
Jasz-Nagykun-Szolnok in Hungay; Bihor and Arad in
Romania; and Banska Bistrica and Nitra in Slovakia. 
529 skin cancer cases, mean age 63.5 (median 66;
range 2-85), were invited on the basis of histopa-
thological examinations by pathologists. 533 hospital-
based controls, mean age 60 (median 61; range 
28-82), were included in the study, subject to fulfilment
of a set of criteria. Those controls included general
surgery, orthopaedic and trauma patients with conditions
such as appendicitis, abdominal hernias, duodenal ulcers,
cholelithiasis and fractures; patients with malignant
tumours, diabetes and cardiovascular diseases were
excluded. They were also broadly matched with cases for
age, gender, country of residence and ethnicity. 
G Ge en no ot ty yp pi in ng g
DNA was isolated from blood samples from cases
and controls using Qiagen mini-preparation kits and
genotyped for variants in the ARLTS1 gene by direct
DNA sequencing. A 237-bp product containing exon
2 of the ARLTS1 gene was amplified and sequenced
bidirectionally using primers 5’-GAT ATC CTC GTG
TAC GTG CTG (forward) and 5’-GAG CAA AGA TAT
GCT GCT CTG T (reverse). The conditions used for
PCR and sequencing reactions were as described
previously [10]. The sequencing reaction products were
analyzed on an ABI prism 3100 genetic analyzer and
primary sequence data checked using sequence
analysis software (Applied Biosystem, Forster City, CA). 
S St ta at ti is st ti ic ca al l   A An na al ly ys si is s
Genotype frequencies in cases and controls for all
SNPs were tested for deviation from the Hardy-Weinberg
equilibrium using chi^2 or Fisher’s exact test. Age,
gender and nationality adjusted odds ratio (OR), 
95% confidence intervals (CI) for risk of BCC associated
with each genotype and variant allele of five SNPs were
calculated with logistic regression using SAS version 9.1
(SAS Institute, Cary, NC). Relation between genotype and
BCC risk were summarized as global P-values. Linkage
disequilibrium was calculated with Haplotype software
(www.broad.mit.edu/mpg/haploview/documentation.php).
Power calculation was carried out using Power and
Sample Size calculation software version 2.1.31. 
R Re es su ul lt ts s
The genotyping of a 237 bp-fragment of exon 2 of
the ARLTS1 resulted in detection of 5 single nucleotide
polymorphisms in 529 BCC cases and 533 controls.
The sample size of this study was sufficient to detect
under the dominant model the effect of polymorphisms
with a minor allele frequency higher than 0.2 and an
associated OR equal to or higher than 1.5 with 
a power of 80%. Two SNPs (297G>A and 396G>C)
were synonymous, 2 non-synonymous SNPs (392 C>T
and 442 T>C) resulted in P131L and C148R amino
acid changes, and the G446A SNP resulted in W149X
truncating polymorphism. Genotype distribution for all
five polymorphisms based on allele frequencies were
in accordance with Hardy-Weinberg equilibrium. The
minor allele frequencies for five polymorphisms ranged
from 0.01 (396G>C) to 0.45 (442 T>C) (Table 1).
OR and corresponding 95% CI intervals associated
with each genotype and variant allele are detailed in
Table 1. For none of the five polymorphisms was any
statistical significant difference observed for genotype and
allele frequencies between BCC cases and controls. The
analysis of resultant haplotypes due to 5 SNPs in the gene
showed presence of 8 out of 32 possible haplotypes. 
In controls, however, only 4 haplotypes were detected.
The major haplotype GCGTG consisted of common
alleles of all 5 polymorphisms and together with GCGCG
haplotype accounted for over 90 percent of all cases and
controls. However, no differences in distribution of
haplotypes between cases and controls were observed
(Table 2). Linkage disequilibrium was observed between
392 C>T and 442T>C (D’ = 1.0), and between
442T>C and 446G>A (D’ = 1.0) (Fig. 1). However,
the r^2 values for these linkages were only 0.02 and
0.007. The variant T-allele for the P131L (392C>T) poly-
morphism occurred only in the presence of one or two
T-alleles of the C148R (442T>C) polymorphism. Similarly,
A-allele for the W149X (446G>A) polymorphism was
detected only in the presence of the T-allele of the C148T
(442T>C) polymorphism. Consequently, the variant allele
for the W149X (446G>A) polymorphism occurred
together only with the common allele genotype of the
P131L (392C>T) polymorphism. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(1) 27
ARLTS1 polymorphisms and basal cell carcinoma of the skin
D Di is sc cu us ss si io on n
In this study we evaluated the association of
polymorphisms in the ARLTS1 gene with modulation of
BCC risk. Our results showed that none of the coding
sequence polymorphisms in the ARLTS1 gene was
associated with risk modulation of BCC. While data
showed linkage disequilibrium between three of the
polymorphisms, the resultant haplotypes did not show
differential distribution between cases and controls. 
In the initial study the truncating W149X (446G>A)
polymorphism in the ARLTS1 gene was reported to be
associated with increased risk of familial breast cancer;
in latter studies C148R (442T>C) polymorphism in the
gene was also associated with marginal risk of familial
breast cancer and melanoma [9-11]. At the same time
T Ta ab bl le e   1 1. .   Genotype and allele distribution of variants in the ARLTS1 gene in BCC cases and controls 
G Ge en no ot ty yp pe e/ /A Al ll le el le e C Ca as se es s* * C Co on nt tr ro ol ls s O OR R   ( (9 95 5% %C CI I) ) P P- -v va al lu ue e
S99S (297G>A)
GG 487 (92.2) 490 (91.9) 1.0 (referent)
GA 41 (7.7) 43 (8.1) 1.1 (0.7-1.7) 0.81**
G-allele 1015 (96.1)  1023 (96.0) 1.0 (referent)
A-allele 41 (3.9) 43 (4.0) 1.1 (0.7-1.6) 0.81 
P131L (392C>T)
CC 496 (93.9) 508 (95.3) 1.0 (referent)
CT 32 (6.1) 25 (4.7) 1.3 (0.8-2.3) 0.30
C-allele 1024 (97.0)  1041 (97.7) 1.0 (referent)
T-allele 32 (3.0) 25 (2.3) 1.3 (0.8-2.3) 0.31
L132L (396G>C)
GG 527 (99.8) 531 (99.6) 1.0 (referent)
GC 1 (0.2) 2 (0.4) 0.4 (0.1-4.0) 0.40
G-allele 1055 (99.9)  1064 (99.8) 1.0 (referent)
C-allele 1 (0.1) 2 (0.2) 0.4 (0.1-4.0) 0.40
C148R (442T>C)
TT 165 (31.3) 155 (29.1) 1.0 (referent)
TC 250 (47.4) 258 (48.4) 0.9 (0.7-1.2)
CC 113 (21.0) 120 (22.5) 0.9 (0.6-1.2) 0.64
T-allele 580 (54.9) 568 (53.3) 1.0 (referent)
C-allele 476 (45.1) 498 (46.7) 0.9 (0.8-1.1) 0.36
W149X (446G>A)
GG 519 (98.3) 524 (98.3) 1.0 (referent)
GA 9 (1.7) 9 (1.7) 1.5 (0.6-4.0) 0.41
G-allele 1047 (99.2)  1057 (99.2) 1.0 (referent)
A-allele  9 (0.8) 9 (0.8) 1.5 (0.5-3.5) 0.41
*The number of cases and controls included in the study was 529 and 533, respectively. The sequencing for genotyping failed for one sample among cases.
**Global P-values calculated from chi^2 test for genotype as a single event and allele effects were adjusted for age, gender and nationality.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(1) 28
no association was observed with risk of various
sporadic cancers [12-14].
ARLTS1 is a member of the Ras superfamily and
resides on chromosome 13q14, which is frequently
deleted in a variety of haematopoietic and solid tumours
[15, 16]. Promoter hypermethylation of ARLTS1 and
consequent down regulation of expression has been
reported in B-cell chronic lymphocytic leukaemia and
lung cancers [9]. Moreover the restoration of ARLTS1 in
negative ovarian cells has been reported to reduce
tumorigenic potential in nude mice. Functionally, the
W149X polymorphism has been shown to induce
apoptosis in the infected cells at a significantly reduced
level rather than complete ablation [17]. This was
hypothesized as the potential reason for retention of 
a rather drastic polymorphism in the population and
could probably also explain the lack of associations with
many cancer types including the BCC in the present study. 
In an earlier investigation on the same study
population we observed an association of reduced risk
of BCC with a variant allele of the XRCC3 gene and 
a gender-specific increased risk due to a variant in the
NBS1 genes [18]. Both the XRCC3 and NBS1 genes
are involved in the repair of DNA double strand
breaks. While DNA repair capacity is potentially 
a critical determinant of risk of BCC, the results from
this study suggest that influence of ARLTS1 variants on
apoptosis, if any, does not impact the risk of BCC,
which is one of the largest cancer types. However,
despite a large sample size, the power of our study
could be limited for detection of risk associated with
polymorphisms with minor allele frequencies less than
10 percent. Moreover, association studies in general
are linked with poor reproducibility [19]. 
In conclusion, our data show lack of an association
between polymorphisms and resultant haplotypes in
the ARLTS1 gene and risk of BCC. The hypothesis of
association of multiple cancer types with ARLTS1
variants is not supported by the data in this study.
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